# Sojournix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sojournix

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.sojournixpharma.com
- Total disclosed funding: $46M
- Latest round: Series C (Jan 3, 2019)
- Investors on record: 5

## About

Sojournix Inc. is a biotechnology company focused on developing innovative therapeutics for neurological disorders, enhancing treatment options through advanced research methodologies.Founded in 2016 and headquartered in Waltham, US, Sojournix Inc. specializes in creating novel treatment solutions for neurological conditions. The company has successfully completed a total of 4 deals, with its most recent funding round being a Series C in January 2019, where it raised USD 44 mn from investors including Boxer Capital and Frazier Healthcare Partners. CEO Daniel Grau leads the company, which has been strategically positioning itself within the competitive biotech landscape.Sojournix Inc. develops proprietary therapeutics aimed at addressing unmet medical needs in neurological treatment. The company focuses on drug discovery and development, targeting conditions such as depression and anxiety with innovative, scientifically backed approaches, working to improve patient outcomes effectively.Sojournix Inc. operates under a revenue model based on successful product development and potential partnerships with pharmaceutical entities. While specific revenue figures are not disclosed, the company’s financial strategy is built around maximizing the value of its therapeutic innovations through licensing agreements and collaborations.Sojournix Inc. aims to leverage its recent Series C funding of USD 44 mn to accelerate its clinical research initiatives and expand its pipeline of neurological therapies. The company plans to launch new drug candidates in 2022, targeting further clinical trials to enhance treatment offerings. Expansion efforts are focused on entering key international markets, particularly in Europe and Asia, by 2023, thereby broadening its reach and impact in the global biotech arena.

## Funding rounds

- Series C, Jan 3, 2019, $44M — Frazier Healthcare Partners, Venrock, RA Capital Management, Janus Henderson Investors, Boxer Capital
- Series B, Aug 9, 2017 — RA Capital Management
- Series A, May 11, 2016, $2M — RA Capital Management

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B, Series C
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- Janus Henderson Investors — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C